679 results about "Methylation" patented technology

The invention discloses a synthetic method of a water soluble ultraviolet light absorber BP-9. The method mainly comprises the following process steps: (1) carrying out methylation on the main raw materials of 2, 2', 4, 4'-tetrahydroxyl benzophenone, a transition metal salt catalyst and a mixed solvent which is prepared from dichloroethane and anhydrous ethanol in equal parts by weight to obtain 2, 2'-dihydroxyl-4, 4'-dimethoxyl benzophenone; (2) carrying out sulfonation reaction on the main raw materials of methylate, sulfamic acid and C1-C3 halohydrocarbon to obtain 2, 2'-dihydroxyl-4, 4'-dimethoxyl benzophenone-5, 5'-disulfonic acid; and (3) carrying out neutral reaction on the main raw materials of sulfonated product, inorganic base and ethanol water to finally obtain the BP-9 product. The synthetic method disclosed by the invention is few in reaction step, low in cost, high in product purity and stable in quality, and raw materials are easily available.

The application provides a novel DNA methylation marker TAGMe-3 for tumor identification and use thereof. The TAGMe-3 gene sequence region has significant methylation difference between cancer tissues and paracancer tissues. As long as abnormal high methylation state of the TAGMe-3 gene sequence region is detected, the subject is determined to belong to a tumor high-risk population. Moreover, the significant difference of the TAGMe-3 presented between tumor tissues and non-tumor tissues exists in different types of tumors (Pan-cancer) in a wide range.

The invention relates to the field of anti-tumor drugs, and discloses an anti-diffuse large B-cell lymphoma pharmaceutical composition, a preparation method and application thereof, the composition comprises azacitidine and Sanilisoma, the composition can improve the accumulation amount of VDUP1 protein in a cell nucleus through the combination of the methylation effect of DNMT3b on VDUP1 protein and the inhibition of XPO1 activity by Sanilisoma, and the anti-diffuse large B-cell lymphoma pharmaceutical composition can be used for preparing anti-diffuse large B-cell lymphoma. The chemotherapy effect is remarkably improved, the sensitivity of the DLBCL to the Sanisole is remarkably improved, and particularly, the pharmaceutical composition has a remarkable curative effect on R / R DLBCL patients.

The invention discloses an ALS prognosis evaluation system based on UBE2J2 gene methylation and expression level, and relates to the technical field of biomedicine and bioinformatics. Comprising a data acquisition module, a methylation detection module, an expression quantity determination module, a data preprocessing module, a preliminary survival analysis module, a multivariable Cox proportional risk model construction module, an individualized risk index calculation and grouping module and a visualization and clinical application module. By combining UBE2J2 gene methylation and expression quantity analysis, peripheral blood non-invasive detection, standardized experiment and computational analysis process and visual presentation, the method is technically and remarkably superior to the prior art, high accuracy, operability, repeatability and expandability are realized, and the method is suitable for large-scale popularization and application. And the technical defects of single molecular marker, complicated operation, inaccurate prediction and the like in ALS prognosis evaluation in the prior art are overcome.

The invention relates to the technical field of biological detection, and discloses a reagent composition and a kit for detecting cervical cancer and precancerous lesions of cervical cancer and application of the reagent composition and the kit. The reagent composition provided by the invention is used for detecting the methylation degree of a specific marker gene, and the detection sensitivity and specificity of cervical cancer and high-grade cervical cancer precancerous lesions are at a relatively high level. When the reagent composition is used for screening cervical cancer and precancerous lesions of HPV positive people, compared with conventional cytological detection, the colposcope referral rate is greatly reduced, meanwhile, the detection times for definite diagnosis of high-grade cervical lesions or cervical cancer are reduced, and the waste of medical resources and the examination burden of patients are reduced.

The invention discloses a colorectal cancer Septin9 gene methylation detection kit based on a graded anchoring probe, and belongs to the technical field of molecular diagnosis. The graded anchoring probe is composed of a specific capture probe (F1), a precise anchoring probe (R1), a synergistic blocking probe (F2 / R2) and a short chain complementary sequence (S1) which are Septin9 methylation specific probes and can be fixed in a conical pore channel of a nuclear track membrane in a graded manner to form a capture-anchoring-blocking functional chain; during application, a general accumulation body is formed by combining with a Septin9 methylation target, a nuclear track membrane pore channel is blocked, current drop is caused, and detection is realized. Through cooperation of the probe, the nuclear track membrane and the electrochemistry, the problems of insufficient sensitivity, poor stability and poor specificity of traditional detection are solved, and the kit is suitable for ultra-early diagnosis of colorectal cancer.

The invention relates to the technical field of biological detection, and discloses a reagent composition for detecting urothelial carcinoma, a kit and application. The composition provided by the invention is used for detecting the methylation state of a specific target sequence in a characteristic gene of the urinary tract epithelial cancer, and the detection sensitivity and specificity of the urinary tract epithelial cancer are at a relatively high level. The composition provided by the invention can be used for noninvasive urinary tract epithelium cancer screening, and when the composition is used for urinary tract epithelium cancer screening, compared with conventional urine cytology examination and iconography examination, the detection sensitivity is greatly improved, the early screening accuracy of urinary tract epithelium cancer is improved, and the misdiagnosis rate and the missed diagnosis rate are greatly reduced.

Provided are a method and apparatus for training a prediction model, and an electronic device, a computer-readable storage medium and a computer program product. The method is applied to the electronic device, and comprises: pre-training a first prediction model on the basis of a plurality of first-sample whole-genome sequences so as to obtain a second prediction model; extracting target dinucleotide sites from a plurality of dinucleotide sites in each of the first-sample whole-genome sequences, and using, as second-sample whole-genome sequences, sequences within a preconfigured window range containing the target dinucleotide sites; annotating the actual methylation state for the target dinucleotide sites in each of the second-sample whole-genome sequences; and training the second prediction model on the basis of each of the annotated second-sample whole-genome sequences so as to obtain a trained third prediction model, wherein the third prediction model is used for predicting the methylation state of dinucleotide sites in whole-genome sequences to be detected.

Provided herein are methods of identifying methylation status of a nucleic acid, e.g., RNA in a biological sample. Also provided herein are methods for identifying the methylation status of RNA in a biological sample with spatial technology to identify the location of a methylated RNA in the biological sample.

The invention belongs to the technical field of bioinformatics and deep learning, and particularly relates to a DNA methylation site prediction method, system and device and an electronic medium, and the method comprises the following steps: respectively coding single bases in a DNA sequence into four molecular fingerprints, and constructing each base into a molecular map structure; performing high-order feature extraction on the four molecular fingerprints through a multi-layer perceptron to generate molecular fingerprint features; modeling the molecular graph structure by adopting a multi-head graph attention network, calculating and normalizing attention scores among nodes, carrying out weighted summation on neighbor node features, and carrying out multi-head attention fusion to generate molecular graph features; splicing the molecular fingerprint features and molecular map features, and inputting the spliced molecular fingerprint features and molecular map features into a deep convolution gated channel attention module to generate fused features; and obtaining a prediction probability of the fused features, and judging whether the features are methylation sites or not according to the prediction probability. According to the invention, the identification capability of methylation sites can be improved.

The invention relates to the technical field of biomedical detection, in particular to a urinary tract epithelium cancer detection marker composition based on ONECUT2 and DMRTA2 gene methylation, which comprises a CpG island region of an ONECUT2 gene, a CpG island region of a DMRTA2 gene and a kit for detecting urinary tract epithelium cancer. The CpG island region of the ONECUT2 gene is located in chr18: 57441548-57441674, and the CpG island region of the ONECUT2 gene is located in The CpG island region of the DMRTA2 gene is located in chr1: 50418714-50418823, and the CpG island region of the DMRTA2 gene is located in chr1: The kit for detecting urothelial carcinoma comprises a first primer pair and a first probe which are used for specifically detecting the methylation state of the CpG island region of the ONECUT2 gene in the claim 1, and a second primer pair and a second probe which are used for specifically detecting the methylation state of the CpG island region of the DMRTA2 gene. The urinary tract epithelium cancer detection marker composition based on ONECUT2 and DMRTA2 gene methylation has high sensitivity and high specificity, the sensitivity and the specificity are both 90% or above, early-stage and low-grade urinary tract epithelium cancer can be effectively detected, comprehensive coverage is achieved, and the urinary tract epithelium cancer detection marker composition is not only suitable for bladder cancer, but also suitable for upper urinary tract epithelium cancer such as renal pelvis cancer and ureter cancer.

The application discloses a kind of exogenous bacteriophage inoculation methods for strengthening soil microbial arsenic methylation capacity, comprising the following steps: S1. preparation bacteriophage crude extract;S2. preparation concentrated solution;S3. preparation bacteriophage extract;S4. preparation inoculation soil sample;S5. in the 2, 4, 6th day of culture, bacteriophage extract is added to inoculation soil;S6. after three times inoculation, continue to flood culture 9 days.The application proposes a kind of inoculation method for retaining virulent bacteriophage, not retaining original host bacteria, inoculating after flooding two days, and inoculating three times, so that the proportion of lysogenization of bacteriophage in soil after inoculation is increased by 156%~347%, so that arsenic metabolism genes carried by bacteriophage genome can function, the arsenic methylation capacity of soil microorganism is strengthened, and the arsenic methylation capacity is increased by more than 300%, to efficiently methylate arsenic in soil.

The present application relates to a kind of method and kit for detecting methylation cysteine total amount, belong to the field of biotechnology and analytical test.Utilize nucleic acid aptamer with high response to free Hcy, with moderate corresponding state Hcy to construct evanescent wave optical fiber sensor.Complementary strand and tHcy of fluorescently labeled are combined with the nucleic acid aptamer fixed on optical fiber with competition.Fluorescence signal drop value is positively correlated with tHcy concentration in serum.According to the percentage of fluorescence reduction, the tHcy concentration in serum is calculated.The present application detects tHcy only needs 1 microliter serum, after diluting 1000 times, detection is carried out, and the detection result is consistent with commercial enzyme cycle method.Compared with enzyme cycle method, the present application has the advantages of low price, optical fiber can be reused more than 30 times, detection speed is fast, fastest 5 minutes, does not need enzyme, equipment miniaturization, simple operation, etc., has excellent clinical application value.

Provided herein is a method for distinguishing an aberrant methylation level for DNA from a first cell type, including steps of (a) providing a test data set that includes (i) methylation states for a plurality of sites from test genomic DNA from at least one test organism, and (ii) coverage at each of the sites for detection of the methylation states; (b) providing methylation states for the plurality of sites in reference genomic DNA from one or more reference individual organisms, (c) determining, for each of the sites, the methylation difference between the test genomic DNA and the reference genomic DNA, thereby providing a normalized methylation difference for each site; and (d) weighting the normalized methylation difference for each site by the coverage at each of the sites, thereby determining an aggregate coverage-weighted normalized methylation difference score. Also provided herein are sensitive methods for using genomic DNA methylation levels to distinguish cancer cells from normal cells and to classify different cancer types according to their tissues of origin.

The invention discloses a whole genome methylation detection method based on MeDIP-MSRE, and belongs to the technical field of epigenetics detection. According to the method, methylation immunoprecipitation sequencing and a methylation sensitive restriction enzyme technology are innovatively combined, firstly, a methylation specific antibody is used for conducting immunoprecipitation on sample DNA, and whole genome methylation fragments are enriched; then carrying out enzyme digestion on the enriched product by adopting methylation sensitive restriction enzyme, specifically removing an unmethylated DNA region, and reserving a complete methylation sequence; and finally, constructing a methylation map through high-throughput sequencing. According to the method, traditional hydrosulfite chemical conversion is not needed, DNA damage and base conversion deviation caused by the traditional hydrosulfite chemical conversion are avoided, meanwhile, high sensitivity of MeDIP and high specificity of methylation sensitive restriction endonuclease are fused, and the fidelity, sensitivity and specificity of detection are remarkably improved.

Provided herein, inter alia, are methods for sequencing polynucleotides. In addition, provided herein are methods for detecting base modifications, such as methylation interpretation, in polynucleotides by sequencing only native strands. The key innovation of the method is that after hybridization, a second strand is generated, and the second strand is configured to allow the adaptor to be connected to only one end. This limits sequencing to native strands, i.e., unique strands with potential modifications.

The invention relates to the technical field of molecular biology, in particular to a methylation marker for diagnosis of diabetic nephropathy. Specifically, the methylation marker comprises a P site of a CAT gene promoter region and / or an E site of a CAT gene exon 1 region. Based on a detection system combining methylation sensitive restriction enzyme with quantitative PCR, the kit has the advantages of simplicity and convenience in operation, good repeatability, accuracy in quantification and easiness in standardization, and is suitable for low-invasive samples such as peripheral blood. By effectively distinguishing pure type 2 diabetes patients from diabetic nephropathy combined patients, a reliable technical means is provided for risk stratification, early intervention and dynamic monitoring of diabetic people, and the method has good clinical application prospects and popularization value.

The invention provides a methylation marker for detecting liver cancer and application of the methylation marker, and relates to the technical field of biomedicine. The invention provides a methylation marker combination for detecting liver cancer of each stage, the methylation marker combination comprises one or any more of BEST4 sequences of BEST4 genes or genomes, SFMBT2 sequences of SFMBT2 genes or genomes and SPAG6 sequences of SPAG6 genes or genomes, and the combination can accurately distinguish healthy people or patients with liver benign diseases from liver cancer patients and can be used for detecting the liver cancer of each stage. Moreover, early discovery and early treatment of the liver cancer can be realized, and a new direction and possibility are provided for early diagnosis and individualized treatment of the liver cancer. According to the invention, modeling is carried out by using a method based on machine learning, three different liver cancer diagnosis models are constructed, and the models are rapid in diagnosis, can realize in-vitro noninvasive, high-sensitivity and high-specificity diagnosis, and are suitable for wide popularization.

The invention discloses a gene sequencing data management method for whole genome methylation sequencing, and relates to the technical field of gene sequencing data management.The method comprises the steps that original gene sequencing data are obtained and preprocessed, and a regional methylation matrix is generated; calculating a technical difference measure and a phenotype difference measure of each region unit based on the region methylation matrix and the sample metadata, identifying a technical methylation bias domain, and grading the technical methylation bias domain into a steady-state technical methylation bias domain and an event-driven technical methylation bias domain according to the occurrence frequency of the technical methylation bias domain in multiple batches; based on a linear adjacency relation and a co-bias relation, constructing a technical methylation bias super-domain and classifying the technical methylation bias super-domain; performing regional shielding on the methylation bias super-domain of the steady state technology, performing normalization correction on the methylation bias super-domain of the event-driven technology, and generating a corrected regional methylation matrix; calculating a sample quality index based on the corrected matrix and performing quality grading; according to the method, technical bias can be identified and corrected, and the methylation data quality and analysis reliability are improved.

The utility model discloses a portable sampling device for endometrial cancer gene methylation detection in the technical field of sampling devices, which comprises an extraction cylinder, one end of the extraction cylinder is fixedly inserted with a connecting pipe, the inner wall of the connecting pipe is movably inserted with a detachable extraction pipe, and the inner wall of the detachable extraction pipe is movably inserted with a connecting pipe. A plurality of guide blocks are fixedly arranged on the outer wall of the end, inserted into the connecting pipe, of the detachable extraction pipe, the guide blocks are in sliding fit with the inner wall of the connecting pipe, and two toothed plate sealing pieces used for blocking the connecting pipe are movably arranged on the inner wall of the extraction cylinder; after the device is used, the grab handle is firstly detached, then the detachable extraction pipe is detached, and at the moment, the guide block slides along the inner wall of the connecting pipe, so that the connecting pipe drives the transmission gear to rotate reversely, and the two toothed plate sealing pieces are reset along with the reverse rotation of the transmission gear to seal the connecting pipe; therefore, the possibility that external sundries enter the extraction barrel through the connecting pipe when the device is not used is reduced.

This invention provides a methylation biomarker for detecting gastric cancer and its application, relating to the field of molecular biomedical technology. This invention provides a combination of methylation biomarkers for early, non-invasive identification of gastric cancer and their application. Based on the measured expression levels of methylation biomarkers in blood samples from patients with and without gastric cancer, biomarkers for identifying gastric cancer are provided. The biomarker combination of this invention can not only assist clinicians in predicting and diagnosing the risk of patients developing gastric cancer, but also serve as a tool for screening high-risk populations for gastric cancer, helping patients to detect and treat the disease early. Moreover, compared to current gastric cancer early screening products and existing technologies, the detection process of this invention is non-invasive, has higher sensitivity and specificity, the detection method is mature and rapid, the cost is low, the safety is high, and it is convenient for large-scale clinical application.

The present application relates to a machine learning-based pancreatic cancer diagnosis method, and specifically provides a method for constructing a pancreatic cancer diagnosis model, comprising: (1) obtaining the methylation level of a DNA sequence or a fragment thereof, or the methylation state or level of one or more CpG dinucleotides in the DNA sequence or the fragment thereof, and the CA19-9 level of the subject, (2) using a mathematical model to calculate the methylation score using the methylation state or level, (3) combining the methylation score and the CA19-9 level into a data matrix, and (4) constructing a pancreatic cancer diagnosis model based on the data matrix. The method can significantly improve the accuracy of non-invasive diagnosis of pancreatic cancer.

The application discloses a kind of marker for predicting oocyte copy number variation and application thereof, the marker includes the combination of CLEC11A, P4HB, EFEMP2, IL32, FTL, FLNA, COL6A3, ACPP and APOO protein.By the marker of the application, the expression level of granulosa cell secretory protein can be determined by granulosa cell transcriptome sequencing, and the genomic CNV condition of corresponding oocyte can be inferred.The detection object of the technical solution is discarded granulosa cell in assisted reproductive technology, so it will not have any impact on oocyte, and it is non-invasive;The present study is a transcriptome and methylation group detection from single cell level, with high-throughput characteristics, and all granulosa cells and oocytes are one-to-one matched, which can reflect the difference between single cell level COCs.

The invention provides a multiple detection technology MMDEC for high-sensitivity detection of tumor methylated DNA from samples such as blood, belongs to the field of disease diagnosis markers, and more specifically relates to a method for detecting methylation of target DNA through the following steps: constructing oligonucleotide; the kit comprises a target specific multiple Rooptag primer capable of being complementarily combined with a plurality of tumor specific high-methylated CG island target DNAs (Deoxyribose Nucleic Acid) and a universal tag primer combined with the specific multiple Rooptag primer, wherein the target specific multiple Rooptag primer can be complementarily combined with a plurality of tumor specific high-methylated CG island target DNAs (Deoxyribose Nucleic Acid); the method comprises the following steps: performing exponential amplification on multiple methylation target DNA by using a specific multiple Rooptag primer as a primary primer to obtain a multiple amplification product; performing homogeneity amplification on the obtained multiplex amplification primer by using oligonucleotide (which can be complementarily combined with the linearly amplified target DNA) using a universal tag primer as a secondary primer; and detecting whether an amplification product exists or not through a probe. According to the method disclosed by the invention, MMDEC can be used for early screening and diagnosis of plasma / urine sample tumors, accords with clinical practice on the basis of research results, and has a good clinical application prospect.

The present application relates a composition for determining whether a nucleic acid is methylated and a method for determining whether a nucleic acid is methylated.

Described herein are methods and compositions related to methylation-based determination and characterization of subjects afflicted with various stages of cancer, including lung cancer and non-small cell lung cancer (NSCLC). Osimertinib is one of the most common precision therapies in non-small cell lung cancer but nearly all patients eventually progress due to somatic mutations and cellular plasticity that bypass the treatment. Defining the cellular plasticity state with epigenetics will help physicians know when to switch therapies.

This invention relates to the regulation of pancreatic islet cell differentiation by regulatory factors related to N6-adenosine methylation modification of mRNA. Specifically, it relates to the use of (a) the ALKBH5 gene, or its protein, or its promoter; and / or (b) the YTHDF2 gene, or its protein, or its inhibitor, for the preparation of compositions or formulations for (1) promoting the differentiation of endodermal cells into pancreatic islet precursor cells and / or islet organoids; and / or (2) preventing and / or treating diabetes. The ALKBH5 of this invention regulates the N6-adenosine methylation modification of mRNA by... 6 Modification A controls the in vitro differentiation process of human pancreatic cells. Furthermore, the method of this invention holds promise as an effective method for in vitro culture of pancreatic islet cells, and could subsequently be applied to the treatment of diabetes.

The present invention relates to methods and devices for identification and quantification, including low abundance nucleotide base mutations, insertions, deletions, translocations, splice variants, miRNA variants, alternative transcripts, alternative start sites, alternative coding sequences, alternative non-coding sequences, alternative splicing, exon insertions, exon deletions, intron insertions, or other rearrangements and / or methylated nucleotide bases at the genomic level.

The invention provides a composition for detecting colorectal cancer and application thereof, the composition comprises nucleic acid for detecting the methylation state of a target gene, and the target gene is selected from one or more than two of an MSC gene, an FOXE1 gene, a GDF6 gene and a C9orf50 gene. The invention also provides a kit comprising the composition, and application of the composition in preparation of the kit for in-vitro detection of colorectal cancer.